The goal of this randomized controlled double-blind parallel-group interventional trial is to evaluate the effects of of dietary supplementation with a pre-probiotic on patient- and clinician-reported outcomes, and brain tissue metabolism in patients with post-covid fatigue syndrome.

Inclusion Criteria:

• Age 18 - 65 years
• Covid-19 positive test within last 3 months (as documented byvalid PCR or antigentest
• Moderate-to-severe fatigue (20-MFI test total score > 43.5)
• At least one of additional covid-19 related symptoms (anosmia,ageusia,breathingdifficulties,lungpain, body aches, headaches, difficulties concentrating etc.)

Exclusion Criteria:

• Other pulmonary and cardiovascular conditions
• History of dietary supplement use during the past 4 weeks
• Organic gastrointestinal (GI) disorders such as inflammatory bowel disease, coeliac disease, eosinophilic disorders, or current infection of the GI tract.
• Bowel surgery or short bowel syndrome.
• Medication or supplement which can impact the gut microbiome, including: antibiotics, antimicrobials, or antifungals in the two months
• Probiotic or prebiotic supplements in the last 4 weeks

Data obtained through this study may be provided to qualified researchers with academic interest in long COVID. Data will be coded, with no PHI included. Approval of the request and execution of all applicable agreements are prerequisites to the sharing of data with the requesting party.

Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.